Videos

David A. Reardon, MD, clinical director, center for neuro-oncology, Dana-Farber Cancer Institute, discusses the inadequacy of the current standard of care in glioblastoma (GBM).

Kiran Turaga, MD, MPH, surgical oncologist, University of Chicago Cancer Center, speaks on distinguishing between the different subtypes of sarcomas.

Raoul Concepcion, MD, director, Comprehensive Prostate Center, discussed the best treatment option for a patient with metasatic castration-resistant prostate cancer (mCRPC) during the LUGPA Annual Meeting.

Jeffrey Schneider, MD, chief of hematology and medical oncology, Winthrop University Hospital, discusses the benefits of Myriad's myPlan in determining high-risk patients with non-small cell lung cancer (NSCLC).

Debu Tripathy, MD, chair, Breast Medical Oncology, University of Texas MD Anderson Cancer Center, discusses the potential for immunotherapy in the treatment of HER2+ breast cancer.

IMiD Sequencing in Relapsed Myeloma with Keith Stewart, MB, ChB

IMiD Sequencing in Relapsed Myeloma with Keith Stewart, MB, ChB

Mark Stein, MD, medical oncologist, Rutgers Cancer Institute of New Jersey, discusses the future of biomarkers in prostate cancer.

Results from the EF-14 trial which compared standard of care for glioblastoma plus or minus the tumor treating fields. 

Martin van den Bent, MD, Erasmus MC Cancer Center, discusses the results from the ABT-414 trial for patients with brain cancer. 

Howard L. &ldquo;Jack&rdquo; West, MD, thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses the combination of erlotinib plus bevacizumab (Avastin) as a frontline treatment for patients with unresectable advanced, metastatic, or recurrent&nbsp;<em>EGFR</em>-mutant non-small cell lung cancer (NSCLC).

IMiD Sequencing in Relapsed Multiple Myeloma with Paul G. Richardson, MD

IMiD Sequencing in Relapsed Multiple Myeloma with Paul G. Richardson, MD

Catherine Shu, MD, medical oncologist, Division of Hematology/Oncology, Columbia University Medical Center, discusses two clinical trials exploring the use of bevacizumab (Avastin) in patients with non-small cell lung cancer.

Joaquim Bellmunt, MD, PhD, attending physician of Solid Tumor Oncology at Dana-Farber Cancer Institute, discusses the impact of the phase III KEYNOTE-045 study, which compared second- or third-line pembrolizumab with investigator-choice chemotherapy as a treatment for patients with metastatic or locally advanced, unresectable urothelial carcinoma. All patients in the study had recurred or progressed following platinum-based chemotherapy.

Igor Puzanov, MD, professor of oncology, Department of Medicine, Roswell Park Cancer Institute, discusses 2 clinical trials investigating immunotherapy combinations and sequencing in melanoma.

Raymond Osarogiagbon, MD, medical oncologist, Baptist Memorial Medical Group, discusses the significance of surgery quality in non-small cell lung cancer (NSCLC).